PharmaMar´s lurbinectedin transformative data in combination with atezolizumab for small cell lung cancer will be shared as oral presentation at ASCO 2025

PharmaMar (MSE:PHM) a global leader in the research, development, and commercialization of marine-derived oncology therapies, will be present at the American Society of Clinical Oncology (ASCO), that will take place between the 30th of May and the 3rd of June in Chicago, U.S.A. Included among the key presentations an oral abstract of the Phase 3 IMforte trial. “Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for lurbinectedin (Zepzelca®) in combination with atezolizumab (Tecentriq®) underscore potential of first line maintenance therapy for extensive stage small cell lung cancer (ES-SCLC), a much-needed advancement for patients”, commented Javier Jiménez, Chief Medical Officer of PharmaMar. The Company also will host an investor webcast on June 12th to review Phase 3 IMforte data being presented at this year’s ASCO Annual Meeting. The webcast will include commentaries from leading European experts in small cell lung cancer. The webcast can be accessed at https://slingshotinsights.com/projects/4556. Additional details will be provided prior to the webcast.   The full list of PharmaMar or partner-supported presentations at the 2025 ASCO Annual Meeting are: PRODUCTTITLELEAD AUTHORABSTRACT Zepzelca® (lurbinectedin)Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the Phase 3 IMforte trialLuis G. Paz-Ares, MD, PhDTYPE: Oral Abstract   SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers   ABSTRACT: 8006   DATE: June 2nd, 2025 (03:00 PM- 06: PM CDT) Safety and Efficacy of Lurbinectedin Plus Atezolizumab as Second-Line Treatment for Advanced Small-Cell Lung Cancer: Results of the 2SMALL Phase 1/2 Study (NCT04253145)Santiago Ponce, MD, PhDTYPE: Rapid Oral Abstract   SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers   ABSTRACT: 8013   DATE: June 1st, 2025 (04:30 PM- 06:00 PM CDT) Evaluation of combination of lurbinectedin plus atezolizumab in humanized mouse model Antonio Calles, MD, PHDTYPE: e-poster   ABSTRACT: e14614   DATE: May 22nd, 2025 (05:00 PM CDT)

The release as fetched from its publisher. pharmamar.com ↗